Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes
暂无分享,去创建一个
H P Hartung | F Barkhof | C H Polman | F. Barkhof | X. Montalban | L. Kappos | C. Polman | H. Hartung | M. Freedman | G. Edan | C. Pohl | H. Hartung | D H Miller | R. Sandbrink | X Montalban | M S Freedman | L Kappos | L Bauer | C Pohl | G Edan | P Jakobs | R Sandbrink | L. Bauer | D. Miller | P. Jakobs | D. Miller | David H. Miller
[1] D. Paty,et al. Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis , 1993, Neurology.
[2] G. Comi,et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. , 1997, Brain : a journal of neurology.
[3] J H Simon,et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. , 2000, The New England journal of medicine.
[4] C. Wolfson,et al. Do General and Multiple Sclerosis-Specific Quality of Life Instruments Differ? , 2004, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.
[5] C. Granger,et al. Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis , 1996, Annals of neurology.
[6] L. Kappos,et al. Discrepancies in the interpretation of clinical symptoms and signs in the diagnosis of multiple sclerosis. A proposal for standardization , 2005, Multiple sclerosis.
[7] P. O'Connor. The effects of intramuscular interferon beta-Ia in patients at high risk for development of multiple sclerosis: a post hoc analysis of data from CHAMPS. , 2003, Clinical therapeutics.
[8] D. Goodin,et al. The utility of MRI in suspected MS: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. , 2004, Neurology.
[9] G. Karabatsos,et al. Validation of the Functional Assessment of Multiple Sclerosis quality of life instrument , 1996, Neurology.
[10] À. Rovira,et al. New diagnostic criteria for multiple sclerosis: Application in first demyelinating episode , 2003 .
[11] D. Silberberg,et al. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols , 1983, Annals of neurology.
[12] David H. Miller,et al. Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis , 2002, Annals of neurology.
[13] J. Files,et al. A novel bioassay for the determination of neutralizing antibodies to IFN-beta1b. , 1998, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[14] G. Ebers. Prognostic factors for multiple sclerosis: the importance of natural history studies , 2005, Journal of Neurology.
[15] Wolfgang Brück,et al. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. , 2002, Brain : a journal of neurology.
[16] A. Achiron,et al. Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: a randomized, double-blind, placebo-controlled trial. , 2004, Archives of neurology.
[17] S. Reingold,et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria” , 2005, Annals of neurology.
[18] P. Duquette,et al. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. , 1993 .
[19] J. Kurtzke. Rating neurologic impairment in multiple sclerosis , 1983, Neurology.
[20] A. Compston,et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis , 2001, Annals of neurology.
[21] R. Rudick,et al. Axonal transection in the lesions of multiple sclerosis. , 1998, The New England journal of medicine.
[22] Gary G. Koch,et al. Categorical Data Analysis Using The SAS1 System , 1995 .
[23] Marco Rovaris,et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study , 2001, The Lancet.